Page 12 - இ சென் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Anixa Biosciences (ANIX – Research Report) today and set a price target of $11.00. The company’s shares closed last Monday at $4.06. According to TipRanks.com, Chen is a top 100 analyst with an average return of 61.9% and a 50.9% success rate. Chen covers the Healthcare sector, focusing on stocks such as Ortho Clinical Diagnostics Holdings, Interpace Diagnostics Group, and HTG Molecular Diagnostics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Anixa Biosciences with a $11.00 average price target. Based on Anixa Biosciences’ latest earnings release for the quarter ending January 31, the company reported a quarterly revenue of $512.5K and GAAP net loss of $2.21 million. In comparison, last year the company had a GAAP net loss of $2.59 million.

Yi chenAnixa biosciencesAnixa bioscienceInterpace diagnostics groupAnixa biosciences incOrtho clinical diagnostics holdingsRating updateResearch reportModerate buyCancer diagnosticsCancer therapeuticsLegacy patent licensingCancer diagnosticSan joseஇ சென்எலும்பியல் மருத்துவ பரிசோதனை ஹோல்டிங்ஸ்